Study S001203

An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition

ClinicalTrials.gov record

Registration

Registration: NCT06422624
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: UNKNOWN
Enrollment: 14
Start: 2024-08
Primary completion: 2024-11
Lead sponsor: Bostal Drug Delivery Co., Ltd
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide Extended-release for Injectable Suspension, 1 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 4 mg; DRUG:Semaglutide Extended-release for Injectable Suspension, 8 mg
Results posted: FALSE

Registered primary outcomes

Cmax [From time zero up to the last time point with measurable concentration]
AUC0-t [From time zero up to the last time point with measurable concentration]
AUC0-inf [From time zero up to the last time point with measurable concentration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.